Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

estrogen receptor degrader AC699

An orally bioavailable estrogen receptor (ER)-targeted chimeric protein degrader composed of ligands of ER and cereblon (CRBN) E3 ubiquitin ligase, with potential antineoplastic activity. Upon oral administration of ER degrader AC699, the ER-targeting moiety targets and binds to ER, and the CRBN-binding moiety recruits CRBN, a component of the CRL4-CRBN E3 ubiquitin ligase complex. This catalyzes ubiquitination and proteasome-mediated degradation of ER, prevents ER-mediated signaling, and inhibits both the growth and survival of ER-expressing cancer cells. ER is overexpressed in a variety of cancers and plays a key role in cancer cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ER degrader AC699
ER-targeting chimeric protein degrader AC699
Code name:AC 699
AC-699
AC699
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search